HS
ONCT

HighVista Strategies’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

HighVista Strategies’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,156
Closed -$97K – 132
2021
Q3 		$97K Buy
+1,156
New +$95.6K 0.06% 103

Other funds holding ONCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM

HighVista Strategies's ONCT Position: Q4 2021 in Review

HighVista Strategies sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2021, closing a stake of 1,156 shares — an estimated $97K sold.

HighVista Strategies first reported a position in ONCT in Q3 2021 and held it in 1 quarter. The position peaked at $97K in Q3 2021. 82 funds tracked by Wall St. Rank hold ONCT as of Q4 2021.

  • HighVista Strategies reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • HighVista Strategies sold 1,156 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $97K.
  • HighVista Strategies first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • HighVista Strategies's Oncternal Therapeutics, Inc. Common Stock position peaked at $97K in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2021.

Based on HighVista Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.